sur The Vanguard Group, Inc. (isin : US12572Q1058)
The Vanguard Group Reports Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has disclosed its interests in Avadel Pharmaceuticals plc under Form 8.3, as per the Irish Takeover Panel regulations. As of January 5, 2026, Vanguard holds 5,862,436 US$0.01 ordinary shares, representing 6.02% of the company's relevant securities.
No cash-settled or stock-settled derivatives, nor any agreements to purchase or sell additional shares, have been reported. However, Vanguard recently purchased 948 of these shares at a rate of 21.50 USD per unit.
The disclosure indicates that no indemnity, option, or other arrangements exist involving the disclosed securities. Moreover, there are no agreements relating to the voting rights or future acquisition/disposal connected to any derivative.
R. E.
Copyright © 2026 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de The Vanguard Group, Inc.